These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38521448)

  • 1. Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach.
    Cheung YYH; Lau EHY; Yin G; Lin Y; Jiang J; Cowling BJ; Lam KF
    Int J Infect Dis; 2024 Jun; 143():107012. PubMed ID: 38521448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study.
    Lai FTT; Wang B; Wei C; Chui CSL; Li X; Cheung CL; Wong ICK; Chan EWY; Wan EYF
    Age Ageing; 2024 Aug; 53(8):. PubMed ID: 39141078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong.
    Cheung YYH; Lau EHY; Yin G; Lin Y; Cowling BJ; Lam KF
    Emerg Infect Dis; 2024 Jan; 30(1):70-78. PubMed ID: 38040664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.
    Shah MM; Joyce B; Plumb ID; Sahakian S; Feldstein LR; Barkley E; Paccione M; Deckert J; Sandmann D; Hagen MB; Gerhart JL
    Clin Infect Dis; 2024 Jul; 79(1):108-110. PubMed ID: 38411622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.
    Wang H; Wei Y; Hung CT; Lin G; Jiang X; Li C; Jia KM; Yam CHK; Chow TY; Ho JY; Wang Y; Zhao S; Guo Z; Li K; Yang A; Mok CKP; Hui DSC; Yeoh EK; Chong KC
    Lancet Infect Dis; 2024 Oct; 24(10):1130-1140. PubMed ID: 38710190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
    Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
    JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
    Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
    Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
    Paraskevis D; Gkova M; Mellou K; Gerolymatos G; Psalida N; Gkolfinopoulou K; Kostaki EG; Loukides S; Kotanidou A; Skoutelis A; Thiraios E; Saroglou G; Zografopoulos D; Filippou D; Mossialos E; Zaoutis T; Gaga M; Tsiodras S; Antoniadou A
    J Infect Dis; 2023 Dec; 228(12):1667-1674. PubMed ID: 37565522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antivirals for COVID-19 among patients with cancer.
    Guermazi D; Arvanitis P; Vieira K; Warner JL; Farmakiotis D
    Support Care Cancer; 2024 Jul; 32(8):496. PubMed ID: 38980433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
    Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.